Source: SlayNews.com (via BlacklistedNews.com)
The Food and Drug Administration (FDA) is preparing to authorize the latest COVID-19 booster shots, developed for the Omicron variant, without first running trials on humans.
Instead, the vaccines will rely on testing on mice and will be approved for public use months before human trials are complete.
The new Omicron shots will be approved by the FDA this week, the Wall Street Journal reported.
The new booster shot will be “bivalent,” meaning it can target the original COVID-19 strain and the Omicron BA.5 subvariant.
Despite not having been tested on humans, the vaccination will likely be available to all Americans.
Aside from testing on mice, the FDA will also rely on data from current COVID-19 vaccines, and earlier iterations of boosters.
The Wall Street Journal noted, “The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.”…